I'm Jim Kramer and you're about to hear a sample taken directly from today's

CBC Investing Club morning meeting.

Eli Lilly.

Well, it's a big win today for Eli Lilly's.

You can see the stock up almost 15%.

It's not done.

It's not because it became a one horse race after this because the pill people hate shots at 80%

people hate shots so they tend to get off injections so they get off this thing before they

should they don't let you go kottom kutong these are all like I take this one for my brain

and it does hurt and I don't like it yeah I always have to have to look forward to Monday. I have to take it. I don't want it. If I had a pill, I'd take it a second. This is a pill. Yeah. So we're talking, of course, about an oral GLP1 pill, phase three data, Eli Lilly, announced today. And this is for a diabetes trial, not obesity, but that one's coming in the third quarter.

But it was good.

Wagovi, OZembeck like efficacy.

So you're getting an injection like efficacy but through a once daily pill.

But most importantly, the safety and tolerability, very consistent with injectable therapy.

So that was a big win.

We've seen other companies struggle with some of the safety and tolerability issues.

Pfizer just continued working on their pill because of safety and tolerability.

Vikings nowhere.

Remember that Viking was supposed to be something?

Yeah.

Look, I mean, that's a, it is now a very small biotech now.

But I think regenerum has something, but in two years.

...